Please login to the form below

renal cell carcinoma

This page shows the latest renal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Keytruda combo outshines Opdivo in kidney cancer

has landed a blow against rivals BMS and its lead in immunotherapy treatment of renal cell carcinoma (RCC). .

Latest news

EU approval for Opdivo combo in renal cell cancer

poor-risk advanced renal cell carcinoma (RCC). ... For now though, BMS is one step ahead. “Currently, less than 50% of patients with metastatic renal cell carcinoma survive beyond two years, and there is almost no complete remission observed,
Nektar confirms BMS deal for NKTR-214 is on track

studies of NKTR-214 in front-line and second-/third-line non–small-cell lung cancer (NSCLC) in the second-quarter, and are now working on 20 indications across nine tumour ... and sarcoma, adding to the previously-disclosed studies in melanoma, renal
Roche pulls EU Tecentriq/Avastin filing in kidney cancer

Roche has opted to withdraw its filing in Europe for a dual regimen for renal cell carcinoma based on checkpoint inhibitor Tecentriq and Avastin, on the grounds that the data supporting ... line use of the pair in non-small cell lung cancer (NSCLC) based
BMS CEO tackles investor ‘frustrations’ on immuno-oncology

Company faces pressure from competitors in renal cell carcinoma. Bristol-Myers Squibb chief executive Giovani Caforio barely mentioned the company’s finances on its third-quarter results call before launching into ... that BMS’ was the first company
Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress. Merck &Co could steal the thunder of its German namesake Merck KGaA after reporting strong survival data for Keytruda in front-line renal cell carcinoma, ... Pfizer when it presents the JAVELIN Renal 101 study of its

More from news
Approximately 7 fully matching, plus 124 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

The JAVELIN Renal 101 trial combining Bavencio with Inlyta in previously untreated advanced renal cell carcinoma recently showed itself to be superior in progression- free survival (PFS) compared with Sutent. ... Pfizer also has a considerable stake in
Charting a course for expansion

Its first US approval came in April for second-line treatment of renal cell carcinoma (RCC), a prevalent and difficult-to-diagnose cancer, with European regulators giving it the green light ... It showed that Cabometyx can decrease the rate of disease
Deal Watch March 2016

Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).
Deal Watch December 2015

510. SQZ Biotech (US). Roche. Collaboration, licence. B cell engineering platform to discover oncology targets . ... 405. Aveo (US). EUSA. Collaboration, licence. Pre-registration tivozanib for renal cell carcinoma.
Pharma deals during April 2014

Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

AVEO appoints Nikhil Mehta as its senior VP, regulatory and quality assurance

and oncology that we believe will be invaluable as we plan and advance our US registration strategy for tivozanib as a potential treatment for renal cell carcinoma.”.
CytomX appoints Rachel Humphrey chief medical officer

Humphrey also spent time at Bayer where she oversaw the early and late stage clinical development of the renal cell carcinoma treatment Nexavar (sorafenib).
Bayer’s former oncology head Robert Rosen joins AP Pharma

During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

While at Bayer Rosen led launch of Nexavar for renal cell carcinoma and hepatocellular carcinoma. ... Rosen was in charge of Bayer's oncology efforts from 2005 to 2011, where he led the launch of Nexavar (sorafenib) for the treatment of renal cell

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Cell Carcinoma.
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?

In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate risk renal-cell carcinoma (RCC) patients. ... In the CABOSUN trial, cabozantinib was compared to sunitinib in treatment naive poor and intermediate
A stumble, but not a fall – what’s next for Opdivo?

and renal cell carcinoma (kidney cancer). ... Back then, the UK’s cost-effectiveness watchdog NICE deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower

More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Home-based Medical Writer – Medical Education: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director, Healthcare Marketing Agency: Salary TBC

Home-based Senior Medical Writer – Med Ed: Salary TBC

Freelance Senior Account Manager / Account Director - Healthcare...: £350-400 depending on experience

Freelance AM/ AD Healthcare Advertising: £350-400 depending on experience

Senior Medical Writer: Salary TBC

Senior Account Manager, Medical Communications, London: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

EU Head of Business Development and Client Service: Exceptional packge and bonus

Scientific Director – Medical Communications: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Health Consultant - Brand Comms: Competitive Salary

Creative/ Medical Writer: Circa £35, 000 With Benefits

Digital Account Director: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Digital Health Specialist – Global Agency: Salary TBC

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Home based, Senior Medical Writer, Medical Communications: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...